NIKKEI 225
27,693.65 +184.19 (+0.67%) HANG SENG
21,222.16 -438.31 (-2.02%) CRUDE OIL
74.30 +0.91 (+1.24%) GOLD FUTURES
1,878.50 +1.90 (+0.10%) DOW
33,885.68 -40.33 (-0.12%) BTC-GBP
19,130.77 +5.59 (+0.03%)
MRK Feb 2023 100.000 call
| Previous close | 3.8600 |
| Open | 4.2200 |
| Bid | 4.7500 |
| Ask | 4.9000 |
| Strike | 100.00 |
| Expiry date | 2023-02-17 |
| Day's range | 3.7000 - 4.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.39k |
- Reuters
Drug companies face COVID cliff in 2023 as sales set to plummet
Pharmaceutical companies that made billions from the pandemic over the past two years selling vaccines and treatments are now up against a steep COVID cliff and investor pressure to spend their windfalls wisely. Western drugmakers including Pfizer Inc, BioNTech SE, Moderna Inc, Gilead Sciences Inc, AstraZeneca Plc and Merck & Co are estimated to have brought in about $100 billion in revenue from COVID vaccines and treatments in 2022. Company and analyst estimates suggest those sales could fall by nearly two-thirds this year due to built up product inventories around the world including in the countries that pay the most.
- Simply Wall St.
Merck Full Year 2022 Earnings: EPS Misses Expectations
Merck ( NYSE:MRK ) Full Year 2022 Results Key Financial Results Revenue: US$59.3b (up 22% from FY 2021). Net income...
- Zacks
AbbVie Q4 Preview: What's in Store?
AbbVie has put in a mixed earnings performance, exceeding bottom line estimates in five consecutive quarters but falling short of sales expectations in each instance.
